AstraZeneca Plc shares plunged in London, erasing about £14 billion ($18 billion) of market value, amid escalating concerns ...

AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...

We recently compiled a list of the 10 Best UK Stocks to Invest in Now. In this article, we are going to take a look at where ...

AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it ...

Two current and two former senior AstraZeneca Plc executives in the group’s China unit are under investigation in a probe ...

The AstraZeneca PLC ADR AZN inched 0.01% higher to $71.43 Monday, on what proved to be an all-around grim trading session for ...

AstraZeneca and Eccogene revealed promising trial data on ECC5004, an oral GLP-1 receptor agonist for obesity, showing safety ...

AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps. Chronic rhinosinusitis is a disorder characterised by ...

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AstraZeneca (AZN – Research Report). The company’s ...

AstraZeneca PLC, maintaining its operations in China, remains steadfast amidst speculative media scrutiny concerning ongoing ...

According to a study by Coherent market Insights, and is expected to grow at a CAGR of 11.3% in terms of revenue over the forecast period (2024-2031). Mr. Shah Coherent Market Insights Pvt. Ltd. +1 ...

AstraZeneca and Eccogene presented early data from trials on ECC5004 for obesity, showing consistent safety and tolerability. In trials, ECC5004 displayed a linear PK profile and was unaffected by ...